Point72 Asia (Singapore) Pte. Ltd. Pyxis Oncology, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 18,057 shares of PYXS stock, worth $81,437. This represents 0.01% of its overall portfolio holdings.
Number of Shares
18,057
Previous 19,228
6.09%
Holding current value
$81,437
Previous $21.2 Million
89.53%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PYXS
# of Institutions
74Shares Held
22.6MCall Options Held
21.5KPut Options Held
0-
Laurion Capital Management LP New York, NY3.63MShares$16.4 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$12.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.5MShares$11.3 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.16MShares$9.76 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY1.18MShares$5.31 Million0.01% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $158M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...